Research Papers:

Molecular and functional characterization of a new 3′ end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib

Vittorio Perfetti, Erik Laurini, Suzana Aulić, Maurizio Fermeglia, Roberta Riboni, Marco Lucioni, Elena Dallera, Sara Delfanti, Luigi Pugliese, Francesco Saverio Latteri, Andrea Pietrabissa and Sabrina Pricl _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:56158-56167. https://doi.org/10.18632/oncotarget.19341

Metrics: PDF 1888 views  |   HTML 2577 views  |   ?  


Vittorio Perfetti1,*, Erik Laurini2,*, Suzana Aulić2, Maurizio Fermeglia2, Roberta Riboni3, Marco Lucioni3, Elena Dallera3, Sara Delfanti4, Luigi Pugliese5, Francesco Saverio Latteri6, Andrea Pietrabissa5 and Sabrina Pricl2

1Internal Medicine, Ospedale SS Annunziata-ASST Pavia and Department of Molecular Medicine University of Pavia, 27100 Pavia, Italy

2Molecular Simulation Engineering (MOSE) Laboratory, Pharmaceutical and Molecular Biology Division, DEA, University of Trieste, 34127 Trieste, Italy

3Department of Molecular Medicine and Anatomic Pathology Section, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy

4Department of Oncology and Hematology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy

5Department of Surgery, General Surgery II, University of Pavia and Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy

6General Surgery, Ospedale Cannizzaro, 95126 Catania, Italy

*These authors contributed equally to this work and are First co-authors

Correspondence to:

Sabrina Pricl, email: [email protected]

Keywords: KIT, GIST, novel deletion mutation, Imatinib, neoadjuvant treatment

Received: April 27, 2017     Accepted: June 28, 2017     Published: July 18, 2017


Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs express the receptor tyrosine kinase KIT, and the majority of GISTs present KIT gain-of-function mutations that cluster in the 5' end of the receptor juxtamembrane domain. On the other hand, little information is known about GISTs carrying mutations in the 3′ end of the KIT juxtamembrane domain. Here we report and discuss a clinical case of localized duodenal GIST whose molecular characterization revealed the presence of a new 21 nucleotide/7 amino acid deletion in the 3′ end of KIT juxtamembrane domain (Δ574–580). The patient was treated with Imatinib at standard regimen dose (400 mg/day), and responded well as the original tumor mass reduced, ultimately allowing conservative surgery. In line with these clinical evidences computer simulations, biophysical techniques and in vitro experiments demonstrated that the receptor tyrosine kinase KIT carrying the Δ574–580 mutation displays constitutive phosphorylation, which can be switched-off upon Imatinib treatment. In addition, results from this study showed that a clinical useful procedure, neoadjuvant treatment, can occasionally be of value for the understanding of the molecular pathogenesis of GIST.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19341